Daniel E. Pleguezuelo

Dr. Daniel E. Pleguezuelo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in Nature
Verified
Journal Article
Closed access
PDF file
NMNadia Mercader
Nadia Mercader
ELEsther Leonardo
Esther Leonardo
NANatalia Azpiazu
Natalia Azpiazu
ASAntonio Serrano
Antonio Serrano
GMGinés Morata
Ginés Morata
MTMiguel Torres
Miguel Torres

16 October 2000 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
CJConcepción Jiménez
Concepción Jiménez
RPRosario Armas Portela
Rosario Armas Portela
MMMario Mellado
Mario Mellado
JRJose Miguel Rodríguez-Frade
Jose Miguel Rodríguez-Frade
JCJohn Collard
John Collard
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera
Cell migration represents an important cellular response that utilizes cytoskeletal reorganization as its driving force. Here, we describe a new signaling cascade linking PDGF receptor stimulation to actin rearrangements and cell migration. We demonstrate that PDGF activates Cdc42 and its downstream effector N-WASP to mediate filopodia formation, actin stress fiber disassembly, and a reduction in focal adhesion complexes. Induction of the Cdc42 pathway is independent of phosphoinositide 3-kinase (PI3K) enzymatic activity, but it is dependent on the p85α regulatory subunit of PI3K. Finally, data are provided showing that activation of this pathway is required for PDGF-induced cell migration on collagen. These observations show the essential role of the PI3K regulatory subunit p85α in controlling PDGF receptor–induced cytoskeletal changes and cell migration, illustrating a novel signaling pathway that links receptor stimulation at the cell membrane with actin dynamics.

1 October 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
RLRocio Laguna-Goya
Rocio Laguna-Goya
AUAlberto Utrero-Rico
Alberto Utrero-Rico
PTPaloma Talayero
Paloma Talayero
MLMaria Lasa-Lazaro
Maria Lasa-Lazaro
ARAngel Ramirez-Fernandez
Angel Ramirez-Fernandez
EPEstela Paz-Artal
Estela Paz-Artal
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. Our aim was to develop a model able to predict the risk of fatal outcome in patients with COVID-19 that could be used easily at the time of patients' arrival at the hospital. We constructed a prospective cohort with 611 adult patients in whom COVID-19 was diagnosed between March 10 and April 12, 2020, in a tertiary hospital in Madrid, Spain. The analysis included 501 patients who had been discharged or had died by April 20, 2020. The capacity of several biomarkers, measured at the beginning of hospitalization, to predict mortality was assessed individually. Those biomarkers that independently contributed to improve mortality prediction were included in a multivariable risk model. High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) level, ferritin level, d-dimer level, neutrophil count, and neutrophil-to-lymphocyte ratio were all predictive of mortality (area under the curve >0.70), as were low albumin level, lymphocyte count, monocyte count, and ratio of peripheral blood oxygen saturation to fraction of inspired oxygen (SpO2/FiO2). A multivariable mortality risk model including the SpO2/FiO2 ratio, neutrophil-to-lymphocyte ratio, LDH level, IL-6 level, and age was developed and showed high accuracy for the prediction of fatal outcome (area under the curve 0.94). The optimal cutoff reliably classified patients (including patients with no initial respiratory distress) as survivors and nonsurvivors with 0.88 sensitivity and 0.89 specificity. This mortality risk model allows early risk stratification of hospitalized patients with COVID-19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to guide clinical decision making.

15 July 1998 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MMM. Mellado
M. Mellado
JRJ. M. Rodríguez-Frade
J. M. Rodríguez-Frade
AMAragay Anna M.
Aragay Anna M.
GRG. del Real
G. del Real
AMA. M. Martín
A. M. Martín
CMC. Martínez-A.
C. Martínez-A.
The chemokines are a growing family of low m.w., 70- to 80-residue proinflammatory cytokines that operate by interacting with G protein-coupled receptors. Chemokines are involved in cell migration and in the activation of specific leukocyte subsets. Using the Mono Mac 1 monocytic cell line, we show that monocyte chemotactic protein 1 (MCP-1) triggers activation of the Janus kinase 2 (JAK2)/STAT3 pathway and CCR2 receptor tyrosine phosphorylation. Both Ca2+ mobilization and cell migration are blocked in Mono Mac 1 cells by tyrphostin B42, a specific JAK2 kinase inhibitor. Within seconds of MCP-1 activation, JAK2 phosphorylates CCR2 at the Tyr139 position and promotes JAK2/STAT3 complex association to the receptor. This MCP-1-initiated phosphorylation and association to JAK2 is also observed in CCR2B-transfected HEK293 cells. In contrast, when a CCR2B Tyr139Phe mutant is expressed in HEK293 cells, it is not phosphorylated in tyrosine and triggers neither JAK2/STAT3 activation nor Ca2+ mobilization in response to MCP-1. These results implicate the tyrosine kinase pathway in early chemokine signaling, suggesting a key role for this kinase in later events.

26 February 2021 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
FGFrancisco Javier Gil-Etayo
Francisco Javier Gil-Etayo
PSPatricia Suàrez-Fernández
Patricia Suàrez-Fernández
OCOscar Cabrera-Marante
Oscar Cabrera-Marante
DADaniel Arroyo
Daniel Arroyo
SGSara Garcinuño
Sara Garcinuño
ASAntonio Serrano
Antonio Serrano
The immune response type organized against viral infection is determinant in the prognosis of some infections. This work has aimed to study Th polarization in acute COVID-19 and its possible association with the outcome through an observational prospective study. Fifty-eight COVID-19 patients were recruited in the Medicine Department of the hospital “12 de Octubre,” 55 patients remaining after losses to follow-up. Four groups were established according to maximum degree of disease progression. T-helper cell percentages and phenotypes, analyzed by flow cytometer, and serum cytokines levels, analyzed by Luminex, were evaluated when the microbiological diagnosis (acute phase) of the disease was obtained. Our study found a significant reduction of %Th1 and %Th17 cells with higher activated %Th2 cells in the COVID-19 patients compared with reference population. A higher percent of senescent Th2 cells was found in the patients who died than in those who survived. Senescent Th2 cell percentage was an independent risk factor for death (OR: 13.88) accompanied by the numbers of total lymphocytes (OR: 0.15) with an AUC of 0.879. COVID-19 patients showed a profile of pro-inflammatory serum cytokines compared to controls, with higher levels of IL-2, IL-6, IL-15, and IP-10. IL-10 and IL-13 were also elevated in patients compared to controls. Patients who did not survive presented significantly higher levels of IL-15 than those who recovered. No significant differences were observed according to disease progression groups. The study has shown that increased levels of IL-15 and a high Th2 response are associated with a fatal outcome of the disease.

11 January 2004 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PHPatricia Hernanz-Falcón
Patricia Hernanz-Falcón
JRJosé Miguel Rodríguez-Frade
José Miguel Rodríguez-Frade
ASAntonio Serrano
Antonio Serrano
DJDavid Juan
David Juan
ASAntonio Del Sol
Antonio Del Sol
MMMario Mellado
Mario Mellado